tion and was associated with a decrease rather than an increase in the low MDRJ mRNA level. To test whether a decrease in MDRJ mRNA indirectly affected resistance in these cells, we introduced a MDRIspecific hammerhead ribozyme into wild-type SW-1573 cells. Although this led to a substantial reduction in MDR] mRNA, it did not result in resistance. In all resistant clones we found an altered form of the multidrug resistance-associated protein (MRP), migrating slightly slower during SDS-polyacrylamide gel electrophoresis than MRP in parental cells. This altered MRP was also present in non-P-gp MDR somatic cell hybrids of the SW-1573 Selection of the human non-small-cell lung cancer cell line SW-1573 for resistance to doxorubicin can result in two types of multidrug resistance (MDR): high-level resistance due to P-glycoprotein encoded by the MDR1 gene , a well-defined form of MDR (reviewed by Endicot and Ling, 1988; Roninson, 1991; Schinkel and Borst, 1991; Gottesman and Pastan, 1993; Moscow et al., 1993) ; and low-level resistance associated with a complex phenotype that includes a decrease rather than an increase in MDR1 expression, a decrease in topoisomerase (topo) IIa mRNA and a decreased drug uptake (Eijdems et al., 1992) . This form of non-P-gp MDR was first identified in three independent SW-1573 mutants (Keizer et al., 1989; Baas et al., 1990; Kuiper et al., 1990) and it results in resistance to drugs affecting the function of topoisomerase II (topo II) such as daunorubicin, VP16-213 and m-AMSA [4'-(9-acridinylamino)methanesulphon-m-anisidine], to the membrane-active compound gramicidin D and to drugs affecting the polymerisation of microtubules such as the vinca alkaloids and colchicine (Keizer et al., 1989; Baas et al., 1990; Kuiper et al., 1990; Eijdems et al., 1992) . In somatic cell fusions we have shown that the MDR phenotype, the reduced drug accumulation and the reduction in MDR1 P-gp mRNA are transferred together to drug-sensitive SW-1573 cells, but that the alteration in topo IIa is not genetically linked to the non-P-gp MDR phenotype (Eijdems et al., 1992) .
Several other non-P-gp MDR cell lines have been selected (reviewed in Cole, 1992) and are being used to identify the mechanism(s) underlying this form of resistance. Cole et al. (1992) , identified the multidrug resistance-associated protein (Krishnamachary and Center, 1993; Slovak et al., 1993; Zaman et al., 1993; Barrand et al., 1994; Schneider et al., 1994) , suggesting a role for MRP, a member of the ATP-binding cassette transporter superfamily, in these cell lines as well. Recent transfection studies have proved that MRP can confer resistance to a broad range of natural product drugs (Grant et al., 1994; Zaman et al., 1994) by extruding the drugs from the cells .
Since the multiplicity of alterations in the SW-1573 non-Pgp transfected with the xl subunit of the murine sodium/ potassium exchanger (Eijdems et al., 1992) . This clone has similar growth characteristics and drug sensitivity as the original SW-1573 S1 cell line. The sensitivity for MDR drugs was also unaffected by the presence of ouabain in the culture medium. The non-P-gp MDR cell line 1R50b was isolated from the drug-sensitive parental cell line SI by a multistep doxorubicin selection up to 50 nM (Keizer et al., 1989; Baas et al., 1990; Kuiper et al., 1990) Zaman et al., 1993) . In all experiments a probe for y-actin (Enoch et al., 1986) was included as an internal control. To determine the intensity of the signals for MDRJ, topo IIa, MRP and y-actin mRNA bands, the autoradiographs were scanned on a Bioimage analysis system (Millipore, USA).
Protein immunoblot analysis
Total cell lysates were made by lysis of cells in 10 mM potassium chloride, 1.5 mM magnesium chloride, 10 mM Tris-HCI pH 7.4 and 0.5% (w/v) sodium dodecyl sulphate (SDS) supplemented with 1 mM phenylmethylsulphonyl fluoride (PMSF), leupeptide (2 tg ml-'), pepstatin (1 yg ml-') and aprotinin (2 pg ml-'). DNA was sheared by sonication.
Crude cellular membrane fractions were prepared as described previously (Gerlach et al., 1987) and protein concentrations were measured using the Bio-Rad protein assay (Bio-Rad, Richmond, CA, USA). The protein samples were dissolved in sample buffer [65mM Tris-HCI pH6.8, 2.5% (w/v) SDS, 5% (v/v) glycerol, 5% (v/v) 2-mercaptoethanol], separated on a 7.5% (w/v) polyacrylamide gel containing 0.1% (w/v) SDS and transferred onto nitrocellulose paper (Schleicher and Schuell, Dassel, Germany) by electroblotting. The blots were probed with the monoclonal anti-MRP antibody, MRPrl, raised against a bacterial fusion protein containing amino acids 192-360 of MRP (Flens et al., 1994) .
Antibody was visualised with peroxidase-conjugated rabbit anti-rat immunoglobulins (Dako, Copenhagen, Denmark) followed by enhanced chemiluminescence detection (Amersham, UK). overnight at 30°C as described previously (Schinkel et al., 1993) . High-mannose oligosaccharides were removed by incubation of the crude cellular membrane fractions with 2 units ml-endoglycosidase H (Endo H; Boehringer Mannheim, Mannheim, Germany) in sodium citrate pH 5.5 (end concentration 50 mM) and 0.2% (w/v) SDS. Incubations were performed overnight at 37°C. For the removal of sialic acids, crude cellular membrane fractions were incubated with 1O units ml-' neuraminidase (type 8) overnight at 4°C.
Results
MDR is frequently selected with low levels of doxorubicin SW-1573 clones, resistant to low levels of doxorubicin, were isolated in a single-step procedure using 25 nM, 30 nM and 40 nM doxorubicin (ICIo of the parental cells is 15 nM). After 3 months of selection, 34 clones were isolated and cultured in the presence of doxorubicin. All clones were analysed for their level of mRNA for MDRI P-gp and topo IIa (see Figure 1 ) and a representative subset of ten clones was chosen and analysed in detail. As expected, all ten clones showed significant resistance to doxorubicin (Table I) . With the exception of clone 5R30, all clones also showed some degree of vincristine resistance (Table I) . We conclude that most clones have a MDR phenotype of the non-P-gp variety, as MDRJ mRNA is reduced rather than elevated in most of them (see below).
Drug accumulation is reduced in the doxorubicin-selected SW-1573 clones To investigate whether drug resistance correlated with reduced drug accumulation in these cell lines, daunorubicin and vincristine accumulation was determined (Table II) . All but two of the doxorubicin-selected clones (25.26 and 40.8) showed a reduced steady-state accumulation of daunorubicin compared with the drug-sensitive parental cell line (Table II) . In most clones this accumulation defect for daunorubicin was due to a drug gradient over the plasma membrane because the drug uptake increased after permeabilisation of the cell membrane by digitonin (Table III) . Despite the lack of an apparent daunorubicin accumulation defect, clone 40.8 showed a significant increase of drug accumulation in the presence of digitonin. No significant differences were found To determine the frequency of topo IIa mRNA reduction, all 34 doxorubicin-selected clones were analysed in RNAse protection assays. The topo Ila mRNA levels of the resistant clones varied from parental levels to less than 20% of parental levels (see Figure lb and Table II for the ten clones analysed in detail). The decrease was at least 2-fold in 8 out of 16 clones isolated at 30 nM doxorubicin and in three out of seven clones isolated at 40 nM doxorubicin.
Statistical analysis of the data for the ten clones that were analysed in detail (Table II) showed a significant reduction of topo IIa levels in six clones (25.26, 5R30, 30.3, 30.14, 40.3, 40.10 ). This suggests that low doxorubicin concentrations can select for cells with lowered topo lla mRNA levels.
FACS analysis showed no significant differences in cell cycle distribution between the clones and the parental cell lines that could account for the observed topo Ia mRNA reduction and the variation between the clones (data not shown). The alterations in topo Ila mRNA level were not due to changes in Zy-actin levels, since similar results were obtained with a probe for P-glucuronidase as internal standard in the RNAse protection experiments (data not shown). The only exception was clone 40.8, which had an increased cell size and increased ratio of y-actin to P-glucuronidase mRNA in the absence of a decreased topo IIaE mRNA level.
MDR clones selected at low levels of vincristine do not exhibit the decrease in topoisomerase lIfi mRNA To test whether a similar type of non-P-gp MDR could be obtained with vincristine as with doxorubicin, we selected an additional set of clones in a single step with 20 or 25 nM Altered MRP is associated with MDR EWHM Eijdems et al 302 vincristine (ICIo of the parental cell line is 2.5 nM). These were the lowest concentrations that still fully eliminated parental background clones. After 6 months of selection, six clones were isolated and cultured in the presence of vincristine. The analysis of these clones is summarised in Figure 2 and Tables I and IV. The vincristine-selected clones resemble their doxorubicin-selected counterparts in several characteristics, i.e. resistance to both doxorubicin and vincristine (Table  I) , decreased drug accumulation (Table III) and a reduced MDRJ P-gp mRNA level (Figure 2 ). However, they differ from the doxorubicin-selected clones in two properties: they lack the reduced topo IIa mRNA level ( Figure 2 ) and they have a much higher vincristine than doxorubicin resistance (Table I) . Whereas the average ratio doxorubicin/vincristine resistance was 1.6 (range 0.8-4.0) for the ten doxorubicinselected clones, it was only 0.3 (range 0.2-0.3) for the six vincristine-selected ones (Table I ). Figure 2 RNAse protection assays to quantify MDR] P-gp, MRP and topoisomerase lla mRNA levels in the SW-1573 clones selected with vincristine. The vincristine concentration used for selection (nM) is used for nomenclature, followed by an identifying clone number. For comparison, RNA of the original non-Pgp MDR cell line 1R50b was also assayed. Ten micrograms of total cytoplasmic RNA from each SW-1573 derivative was used.
The y-actin signal was comparable for the independent experiments. On a longer exposure a very faint band of MDR] mRNA signal was detectable in the vincristine-selected clones and was similar to the signal in the IR50b cell line.
MRP mRNA levels in the resistant SW-1573 clones All new MDR clones showed a slight increase in MRP mRNA level (Figures 2 and 3 , Table IV ). For most individual clones this small increase was not statistically significant, as also observed in initial experiments with the resistant cell line IR50b (Zaman et al., 1993) . We observed large variations in independently isolated RNA preparations, illustrated by the standard deviations in Table IV by immunoblotting. Cell extracts were size fractionated by SDS-PAGE and MRP was detected on blots with a monoclonal antibody raised against a MRP fusion protein (Flens et al., 1994) . Figure 4a (25.10, 30.3A, 30.3M, 30.12, 40.3 and lR5Ob) (Table I) was accompanied by a nearly complete replacement of the 180 kDa protein by the 190 -200 kDa protein (Figure 4a ). The protein with altered mobility was also detectable in the non-P-gp MDR cell hybrids F6.1 and F6.3 (Figure 4b ), which were derived by somatic cell fusion of the non-P-gp MDR cell line 1 R5Ob with drug-sensitive cell line Slou (Eijdems et al., 1992) . This shows that the presence of the 190-200 kDa MRP protein is linked to the non-P-gp MDR phenotype in the SW-1573-derived cell lines.
To analyse the nature of the altered behaviour of MRP on SDS-PAGE, crude cellular membrane fractions of the multidrug-resistant cell lines 1 R5Ob, 30.3M (doxorubicin selected) and 20V2 (vincristine selected) were analysed (Figure 4c ). In the membrane fractions, a single MRP band with a molecular weight in the range of 190-200 kDa was detectable in the resistant cells, in contrast to the 180 kDa protein detectable in the parental, drug-sensitive cell line Slou. Similar to the results obtained with total cell lysates, no major increase in the amount of MRP and protein was detectable in the resistant cell lines (1R50b, 20V2). Only cell line 30.3M, which has a 3-fold elevated MRP mRNA, also showed an increase of MRP epitopes in the membrane fractions.
Treatment of the crude cellular membrane fractions with N-glycanase, which removes N-linked oligosaccharides, resulted in the appearance of a single band in the range of 150kDa in both the parental and in the resistant cell lines (Figure 4c ). This indicates that the altered mobility of MRP in the resistant cell lines is due to differences in posttranslational modification and not to major differences in the protein backbone.
Treatment of purified membrane fractions with endoglycosidase H (Endo H), which removes high-mannose oligosaccharides, did not affect the mobility of MRP either in the resistant cell lines or in the drug-sensitive cell line Slou (data not shown). Removal of sialic acid with neuraminidase reduced the size of MRP protein in both the drug-resistant and the drug-sensitive cells to the same extent and did not alter the difference in mobility (data not shown). These results demonstrate that the 180kDa and the 190-200kDa MRP proteins both contain complex oligosaccharides and must have passed the medial Golgi compartment and reached the trans-Golgi network.
Discussion
We have analysed a large set of drug-resistant variants of the human lung cancer line SW-1573, selected with low concentrations of either doxorubicin or vincristine. We found that the predominant type of resistance is a form of MDR characterised by reduced drug accumulation and decreased MDR] P-gp mRNA levels. Since the degree of resistance correlates with the extent to which drug accumulation is diminished, it seems likely that the lowered intracellular drug concentrations are mainly responsible for resistance in these variants. A diminished drug accumulation has also been observed in other non-P-gp MDR cell lines (reviewed by Cole, 1992) , the H69/AR cell line being the only exception (Cole et al., 1991) .
Overexpression of the MRP gene can confer multidrug resistance associated with reduced drug accumulation in human HeLa cells (Grant et al., 1994) and SW-1573 cells . In several non-P-gp MDR cell lines a role for overexpression of MRP was suggested as well (Krishnamachary and Center, 1993; Slovak et al., 1993; Zaman et al., 1993; Barrand et al., 1994; Schneider et al., 1994 The non-P-gp MDR phenotype with altered MRP, reduced drug uptake and reduced MDR] mRNA was obtained both with doxorubicin and vincristine selection. However, the resistance spectra of the two types of clones differed (Table  I) . This suggests that cells may activate multiple resistance mechanisms, even at these low levels of selection. In the case of doxorubicin selection, the supplementary resistance mechanism probably consists of alterations in topo Ila. Most of the MDR variants selected for doxorubicin resistance contained decreased topo Ilm mRNA levels, and the clones with normal mRNA level may nevertheless contain decreased topo II enzyme activity (Eijdems et al., 1995b 
